United States Biotechnology & Medical Research

Opiant Pharmaceuticals Inc (OPNT)

Track

Ticker: OPNT Exchange: NAS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Opiant Pharmaceuticals Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Sale 27 Jan 2023
Value US$1,832,177.29 | Price 216.57 | Shares 612 (+8.0%)
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2023-01-31 2023-01-27 S Sale
3.3
Gorman Brian
612 +8.0%
216.57
US$1,832,177 		612 +8.0% 216.57 US$1,832,177
2023-01-31 2023-01-27 S Sale
2.7
O'Toole David D

Chief Financial Officer

Officer
29,399 +8.4%
259.47
US$3,010,420 		29,399 +8.4% 259.47 US$3,010,420
2023-01-31 2023-01-27 S Sale
Ellison Mark Jason Heath

Chief Development Officer

Officer
75,503 +49.1%
108.88
US$1,561,803 		75,503 +49.1% 108.88 US$1,561,803
2023-01-31 2023-01-27 S Sale
CRYSTAL ROGER

Chief Executive Officer

Executive Director Large shareholder
1,358 -1.8%
20.26
US$27,513 		1,358 -1.8% 20.26 US$27,513
2023-01-31 2023-01-27 S Sale
Skolnick Phil

Chief Scientific Officer

Officer
480 -2.2%
20.26
US$9,725 		480 -2.2% 20.26 US$9,725
2023-01-09 2023-01-09 S Sale
Skolnick Phil

Chief Scientific Officer

Officer
369 -1.6%
20.20
US$7,454 		369 -1.6% 20.20 US$7,454
2023-01-09 2023-01-09 S Sale
Ellison Mark Jason Heath

Chief Development Officer

Officer
469 -2.4%
20.20
US$9,474 		469 -2.4% 20.20 US$9,474
2023-01-09 2023-01-09 S Sale
2.7
O'Toole David D

Chief Financial Officer

Officer
415 -1.2%
20.20
US$8,383 		415 -1.2% 20.20 US$8,383
2023-01-09 2023-01-09 S Sale
CRYSTAL ROGER

Chief Executive Officer

Executive Director Large shareholder
1,183 -1.5%
20.20
US$23,897 		1,183 -1.5% 20.20 US$23,897
2023-01-05 2023-01-05 S Sale
Skolnick Phil

Chief Scientific Officer

Officer
1,421 -6.0%
20.20
US$28,704 		1,421 -6.0% 20.20 US$28,704
2023-01-05 2023-01-05 S Sale
3.3
Gorman Brian
1,313 -3.9%
20.20
US$26,523 		1,313 -3.9% 20.20 US$26,523
2023-01-05 2023-01-05 S Sale
2.7
O'Toole David D

Chief Financial Officer

Officer
1,600 -4.3%
20.20
US$32,320 		1,600 -4.3% 20.20 US$32,320
2023-01-05 2023-01-05 S Sale
CRYSTAL ROGER

Chief Executive Officer

Executive Director Large shareholder
5,029 -6.1%
20.20
US$101,586 		5,029 -6.1% 20.20 US$101,586
2023-01-05 2023-01-05 S Sale
Ellison Mark Jason Heath

Chief Development Officer

Officer
1,806 -8.3%
20.20
US$36,481 		1,806 -8.3% 20.20 US$36,481
2022-07-21 2022-07-20 S Sale
Ruth Matthew R.

Chief Commercial Officer

Officer
1,084 -3.5%
10.62
US$11,512 		1,084 -3.5% 10.62 US$11,512
2022-07-15 2022-07-14 S Sale
CRYSTAL ROGER

Chief Executive Officer

Executive Director Large shareholder
2,246 -2.6%
11.11
US$24,953 		2,246 -2.6% 11.11 US$24,953
2022-07-15 2022-07-14 S Sale
2.7
O'Toole David D

Chief Financial Officer

Officer
779 -2.1%
11.10
US$8,647 		779 -2.1% 11.10 US$8,647
2022-07-15 2022-07-14 S Sale
3.3
Gorman Brian
691 -2.0%
11.16
US$7,712 		691 -2.0% 11.16 US$7,712
2022-07-15 2022-07-14 S Sale
Skolnick Phil

Chief Scientific Officer

Officer
627 -2.6%
11.85
US$7,430 		627 -2.6% 11.85 US$7,430
2022-06-15 2022-06-15 S Sale
2.4
Sinclair Michael
Non-Executive Director Large shareholder
900 -4.5%
10.60
US$9,540 		900 -4.5% 10.60 US$9,540
2022-06-15 2022-06-14 S Sale
2.4
Sinclair Michael
Non-Executive Director Large shareholder
7,225 -26.4%
10.90
US$78,752 		7,225 -26.4% 10.90 US$78,752
2022-06-15 2022-06-13 S Sale
2.4
Sinclair Michael
Non-Executive Director Large shareholder
5,491 -16.7%
11.09
US$60,895 		5,491 -16.7% 11.09 US$60,895
2022-06-13 2022-06-13 B Purchase
3.7
Collard Craig A
Non-Executive Director
4,037 +8.1%
10.94
US$44,149 		4,037 +8.1% 10.94 US$44,149
2022-06-13 2022-06-10 B Purchase
3.7
Collard Craig A
Non-Executive Director
1,663 +3.5%
11.50
US$19,118 		1,663 +3.5% 11.50 US$19,118
2022-06-13 2022-06-09 S Sale
2.4
Sinclair Michael
Non-Executive Director Large shareholder
7,896 -19.4%
12.25
US$96,726 		7,896 -19.4% 12.25 US$96,726
2022-06-08 2022-06-07 S Sale
2.4
Sinclair Michael
Non-Executive Director Large shareholder
800 -1.9%
12.86
US$10,288 		800 -1.9% 12.86 US$10,288
2022-06-08 2022-06-06 S Sale
2.4
Sinclair Michael
Non-Executive Director Large shareholder
7,688 -15.6%
12.94
US$99,483 		7,688 -15.6% 12.94 US$99,483
2022-06-06 2022-06-03 S Sale
2.4
Sinclair Michael
Non-Executive Director Large shareholder
10,264 -17.3%
13.59
US$139,488 		10,264 -17.3% 13.59 US$139,488
2022-06-06 2022-06-02 S Sale
3.3
Gorman Brian
1,148 -3.4%
13.52
US$15,521 		1,148 -3.4% 13.52 US$15,521
2022-06-06 2022-06-02 S Sale
2.4
Sinclair Michael
Non-Executive Director Large shareholder
9,736 -14.1%
13.88
US$135,136 		9,736 -14.1% 13.88 US$135,136
2022-05-17 2022-05-16 B Purchase
3.7
Collard Craig A
Non-Executive Director
27,150 +129.5%
13.54
US$367,611 		27,150 +129.5% 13.54 US$367,611
2022-05-17 2022-05-16 B Purchase
2.2
Silver Gabrielle Alison
Non-Executive Director
2,500 +13.3%
13.29
US$33,220 		2,500 +13.3% 13.29 US$33,220
2022-05-16 2022-05-13 B Purchase
3.7
Collard Craig A
Non-Executive Director
3,689 +21.3%
10.49
US$38,698 		3,689 +21.3% 10.49 US$38,698
2022-05-16 2022-05-13 B Purchase
2.1
MacDougall Ann L.
Non-Executive Director
3,000 +12.9%
10.93
US$32,778 		3,000 +12.9% 10.93 US$32,778
2022-01-27 2022-01-27 S Sale
CRYSTAL ROGER

Chief Executive Officer

Executive Director Large shareholder
1,995 -2.5%
26.15
US$52,169 		1,995 -2.5% 26.15 US$52,169
2022-01-27 2022-01-27 S Sale
Skolnick Phil

Chief Scientific Officer

Officer
1,518 -6.3%
26.19
US$39,756 		1,518 -6.3% 26.19 US$39,756
2022-01-12 2022-01-10 S Sale
CRYSTAL ROGER

Chief Executive Officer

Executive Director Large shareholder
1,058 -1.3%
30.49
US$32,258 		1,058 -1.3% 30.49 US$32,258
2022-01-12 2022-01-10 S Sale
2.7
O'Toole David D

Chief Financial Officer

Officer
432 -1.2%
30.60
US$13,219 		432 -1.2% 30.60 US$13,219
2022-01-12 2022-01-10 S Sale
Skolnick Phil

Chief Scientific Officer

Officer
385 -1.6%
30.49
US$11,739 		385 -1.6% 30.49 US$11,739
2021-09-14 2021-09-14 B Purchase
3.3
Gorman Brian
12 +0.1%
18.97
US$228 		12 +0.1% 18.97 US$228
2021-09-14 2021-09-14 B Purchase
3.3
Gorman Brian
1,300 +6.4%
19.04
US$24,752 		1,300 +6.4% 19.04 US$24,752
2021-09-13 2021-09-10 B Purchase
3.7
Collard Craig A
Non-Executive Director
9,577 +239.4%
18.18
US$174,110 		9,577 +239.4% 18.18 US$174,110
2021-08-20 2021-08-19 S Sale
2.5
Thomas Thomas T.
Non-Executive Director
400 -6.2%
16.25
US$6,500 		400 -6.2% 16.25 US$6,500
2021-08-20 2021-08-19 S Sale
2.5
Thomas Thomas T.
Non-Executive Director
600 -8.6%
16.20
US$9,720 		600 -8.6% 16.20 US$9,720
2021-08-16 2021-08-16 B Purchase
2.7
O'Toole David D

Chief Financial Officer

Officer
600 +2.6%
15.38
US$9,228 		600 +2.6% 15.38 US$9,228
2021-03-17 2021-03-17 S Sale
2.2
Silver Gabrielle Alison
Non-Executive Director
7,157 -30.3%
11.07
US$79,228 		7,157 -30.3% 11.07 US$79,228
2021-03-17 2021-03-17 S Sale
2.1
MacDougall Ann L.
Non-Executive Director
6,606 -24.1%
11.07
US$73,128 		6,606 -24.1% 11.07 US$73,128
2021-03-17 2021-03-16 S Sale
2.2
Silver Gabrielle Alison
Non-Executive Director
1,949 -11.0%
11.50
US$22,414 		1,949 -11.0% 11.50 US$22,414
2021-03-17 2021-03-16 S Sale
2.1
MacDougall Ann L.
Non-Executive Director
1,949 -8.8%
11.50
US$22,414 		1,949 -8.8% 11.50 US$22,414
2021-03-17 2021-03-15 S Sale
2.2
Silver Gabrielle Alison
Non-Executive Director
3,900 -20.1%
11.64
US$45,396 		3,900 -20.1% 11.64 US$45,396
2021-03-17 2021-03-15 S Sale
2.1
MacDougall Ann L.
Non-Executive Director
5,600 -22.0%
11.63
US$65,128 		5,600 -22.0% 11.63 US$65,128
2020-09-08 2020-09-04 B Purchase
2.5
Thomas Thomas T.
Non-Executive Director
500 +11.1%
8.05
US$4,025 		500 +11.1% 8.05 US$4,025
2020-09-08 2020-09-03 B Purchase
2.5
Thomas Thomas T.
Non-Executive Director
2,500 +125.0%
8.40
US$21,000 		2,500 +125.0% 8.40 US$21,000
2020-06-11 2020-06-11 B Purchase
2.7
O'Toole David D

Chief Financial Officer

Officer
1,000 +7.0%
8.74
US$8,740 		1,000 +7.0% 8.74 US$8,740
2020-06-12 2020-06-10 B Purchase
2.2
Silver Gabrielle Alison
Non-Executive Director
2,730 +152.9%
9.13
US$24,925 		2,730 +152.9% 9.13 US$24,925
2020-05-26 2020-05-26 B Purchase
2.7
O'Toole David D

Chief Financial Officer

Officer
1,000 +7.5%
11.00
US$11,000 		1,000 +7.5% 11.00 US$11,000
2020-01-09 2020-01-08 PlS Planned sale
Skolnick Phil

Chief Scientific Officer
2,842 -28.3%
13.46
US$38,253 		2,842 -28.3% 13.46 US$38,253
2020-01-09 2020-01-07 PlS Planned sale
Skolnick Phil

Chief Scientific Officer
3,043 -42.3%
13.36
US$40,654 		3,043 -42.3% 13.36 US$40,654
2020-01-09 2020-01-07 PlS Planned sale
Skolnick Phil

Chief Scientific Officer
2,900 -33.0%
13.60
US$39,440 		2,900 -33.0% 13.60 US$39,440
2020-01-06 2020-01-06 PlS Planned sale
Skolnick Phil

Chief Scientific Officer
515 -5.5%
13.80
US$7,107 		515 -5.5% 13.80 US$7,107
2020-01-06 2020-01-02 PlS Planned sale
Skolnick Phil

Chief Scientific Officer
700 -7.0%
14.08
US$9,856 		700 -7.0% 14.08 US$9,856
2019-12-12 2019-12-12 B Purchase MacDougall Ann L. Non-Executive Director
5,000 +100.0%
14.54
US$72,700 		5,000 +100.0% 14.54 US$72,700
2019-12-06 2019-12-06 PlS Planned sale Skolnick Phil

Chief Scientific Officer

Officer
800 -100.0%
13.34
US$10,672 		800 -100.0% 13.34 US$10,672
2019-12-06 2019-12-05 PlS Planned sale Skolnick Phil

Chief Scientific Officer

Officer
2,057 -72.0%
13.74
US$28,263 		2,057 -72.0% 13.74 US$28,263
2019-12-04 2019-12-03 PlS Planned sale Skolnick Phil

Chief Scientific Officer

Officer
4,578 -61.6%
13.93
US$63,772 		4,578 -61.6% 13.93 US$63,772
2019-12-04 2019-12-02 PlS Planned sale Skolnick Phil

Chief Scientific Officer

Officer
2,565 -25.7%
14.17
US$36,346 		2,565 -25.7% 14.17 US$36,346
2019-11-26 2019-11-26 B Purchase O'Toole David D

Chief Financial Officer

Officer
100 +1.1%
13.22
US$1,322 		100 +1.1% 13.22 US$1,322
2019-11-25 2019-11-22 B Purchase Silver Gabrielle Alison Non-Executive Director
1,785 +inf%
13.51
US$24,115 		1,785 +inf% 13.51 US$24,115
2019-11-15 2019-11-15 B Purchase
2.7
O'Toole David D

Chief Financial Officer
100 +1.1%
15.00
US$1,500 		100 +1.1% 15.00 US$1,500
2019-11-15 2019-11-15 B Purchase
2.7
O'Toole David D

Chief Financial Officer
1,000 +12.5%
14.91
US$14,910 		1,000 +12.5% 14.91 US$14,910
2019-11-05 2019-11-05 PlS Planned sale
Skolnick Phil

Chief Scientific Officer
2,500 -100.0%
14.89
US$37,225 		2,500 -100.0% 14.89 US$37,225
2019-11-05 2019-11-04 PlS Planned sale
Skolnick Phil

Chief Scientific Officer
299 -10.7%
15.28
US$4,569 		299 -10.7% 15.28 US$4,569
2019-11-05 2019-11-01 PlS Planned sale
Skolnick Phil

Chief Scientific Officer
7,201 -72.0%
15.10
US$108,735 		7,201 -72.0% 15.10 US$108,735
2019-10-03 2019-10-03 PlS Planned sale
Skolnick Phil

Chief Scientific Officer
1,609 -100.0%
14.27
US$22,960 		1,609 -100.0% 14.27 US$22,960
2019-10-03 2019-10-02 PlS Planned sale
Skolnick Phil

Chief Scientific Officer
1,102 -40.6%
14.57
US$16,056 		1,102 -40.6% 14.57 US$16,056
Explore more

More insider trading research around Opiant Pharmaceuticals Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America